MX355020B - Biomarcadores de cancer de pulmon y usos de los mismos. - Google Patents

Biomarcadores de cancer de pulmon y usos de los mismos.

Info

Publication number
MX355020B
MX355020B MX2015017251A MX2015017251A MX355020B MX 355020 B MX355020 B MX 355020B MX 2015017251 A MX2015017251 A MX 2015017251A MX 2015017251 A MX2015017251 A MX 2015017251A MX 355020 B MX355020 B MX 355020B
Authority
MX
Mexico
Prior art keywords
lung cancer
biomarker
individual
values
cancer biomarkers
Prior art date
Application number
MX2015017251A
Other languages
English (en)
Inventor
Riel-Mehan Michael
Gold Larry
Ayers Deborah
Wilcox Sheri
Janjic Nebojsa
Jarvis Thale
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of MX355020B publication Critical patent/MX355020B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)

Abstract

La presente invención se refiere a un método in vitro para ayudar a diagnosticar que un individuo tiene o no tiene cáncer de pulmón, o para proporcionar información acerca de cáncer de pulmón en un individuo, el método caracterizado porque comprende: realizar análisis in vitro para detectar la proteína de biomarcador MMP-12 y al menos un biomarcador seleccionado de C9, MMP-7, ERBB1 y SCF sR en una muestra biológica de un individuo, para proporcionar valores de biomarcador que corresponden cada uno a las proteínas de biomarcador, en donde los valores de biomarcador proporcionan una indicación en cuanto a la probabilidad de que el individuo tenga o no tenga cáncer de pulmón, o en donde los valores y biomarcador proporcionan información acerca del cáncer de pulmón en el individuo.
MX2015017251A 2010-07-09 2011-07-11 Biomarcadores de cancer de pulmon y usos de los mismos. MX355020B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36312210P 2010-07-09 2010-07-09
US201161444947P 2011-02-21 2011-02-21
PCT/US2011/043595 WO2012006632A2 (en) 2010-07-09 2011-07-11 Lung cancer biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
MX355020B true MX355020B (es) 2018-04-02

Family

ID=45441874

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017251A MX355020B (es) 2010-07-09 2011-07-11 Biomarcadores de cancer de pulmon y usos de los mismos.
MX2012014268A MX2012014268A (es) 2010-07-09 2011-07-11 Biomarcadores de cancer de pulmon y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012014268A MX2012014268A (es) 2010-07-09 2011-07-11 Biomarcadores de cancer de pulmon y usos de los mismos.

Country Status (12)

Country Link
US (3) US20130116150A1 (es)
EP (1) EP2591357A4 (es)
JP (1) JP5905003B2 (es)
KR (1) KR101870123B1 (es)
CN (2) CN104777313B (es)
AU (1) AU2011274422B2 (es)
BR (1) BR112012032537B8 (es)
CA (1) CA2801110C (es)
IL (1) IL223295A (es)
MX (2) MX355020B (es)
SG (2) SG10201508656VA (es)
WO (1) WO2012006632A2 (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2021792B1 (en) 2006-05-09 2013-02-27 The University Of British Columbia Dissolved protein arthritis markers
KR20180102215A (ko) 2007-11-27 2018-09-14 더 유니버시티 오브 브리티쉬 콜롬비아 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
US8285719B1 (en) 2008-08-08 2012-10-09 The Research Foundation Of State University Of New York System and method for probabilistic relational clustering
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
WO2010102412A1 (en) 2009-03-11 2010-09-16 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
US20140235487A1 (en) * 2010-11-12 2014-08-21 William Marsh Rice University Oral cancer risk scoring
PT2768851T (pt) 2011-10-21 2017-09-08 Augurex Life Sciences Corp Antigénios derivados de 14-3-3 citrulinada e utilizações dos mesmos no diagnóstico de artrite reumatoide
US20130282390A1 (en) * 2012-04-20 2013-10-24 International Business Machines Corporation Combining knowledge and data driven insights for identifying risk factors in healthcare
EP2841603A4 (en) * 2012-04-26 2016-05-25 Allegro Diagnostics Corp METHODS OF ASSESSING THE STATUS OF LUNG CANCER
JP6022285B2 (ja) * 2012-09-28 2016-11-09 シスメックス株式会社 標本収納装置、標本収納方法、及び標本検査システム
AU2013340414B2 (en) 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN104812913B (zh) 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
EP2935628B1 (en) 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Compositions and methods for aptamer screening
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp METHOD FOR EVALUATING A COPD STATUS
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US9612248B2 (en) 2013-03-15 2017-04-04 Somalogic, Inc. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
WO2014153327A1 (en) 2013-03-18 2014-09-25 Barbeau James M Methods to determine carcinogenesis, identify markers for early cancer diagnosis and identify targets of therapy
WO2014187881A1 (en) * 2013-05-21 2014-11-27 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
KR101552014B1 (ko) 2013-10-11 2015-09-09 인제대학교 산학협력단 폐암 진단을 위한 nir의 신규한 용도
WO2015066564A1 (en) * 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
BR112016010322A2 (pt) 2013-11-07 2017-08-08 Medial Res Ltd Método computadorizado de avaliação de risco de câncer de pulmão, meio legível por computador, sistema de avaliação de câncer de pulmão, e método de geração de um classificador para avaliação de risco de câncer de pulmão
JP6703479B2 (ja) * 2013-12-16 2020-06-03 フィリップ モリス プロダクツ エス アー 個人の喫煙ステータスを予測するためのシステムおよび方法
RU2538625C1 (ru) * 2014-01-20 2015-01-10 Денис Николаевич Бахмутов Способ диагностики рака
WO2015164617A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Tuberculosis biomarkers in urine and uses thereof
WO2015164616A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
WO2015164772A1 (en) * 2014-04-25 2015-10-29 Rush University Medical Center Circulating insulin-like growth factor (igf)-associated proteins for the detection of lung cancer
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114807368A (zh) * 2014-07-14 2022-07-29 威拉赛特公司 用于评估肺癌状态的方法
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2016123058A1 (en) 2015-01-27 2016-08-04 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
WO2016182967A1 (en) 2015-05-08 2016-11-17 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
US20180259533A1 (en) * 2015-09-09 2018-09-13 Somalogic, Inc. Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles
JP6857185B2 (ja) * 2015-09-11 2021-04-14 アプタマー サイエンス インコーポレイテッドＡｐｔａｍｅｒ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
US10546650B2 (en) 2015-10-23 2020-01-28 Google Llc Neural network for processing aptamer data
KR102687249B1 (ko) 2016-02-08 2024-07-22 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간 질환 (nafld)과 비알코올성 지방간염 (nash) 생물마커 및 이들의 용도
JP6041331B1 (ja) * 2016-02-26 2016-12-07 国立大学法人山口大学 情報処理装置と情報処理プログラム並びに情報処理方法
JP6889428B2 (ja) * 2016-02-26 2021-06-18 国立大学法人山口大学 情報処理装置と情報処理プログラム並びに情報処理方法
CN107435062B (zh) * 2016-05-25 2020-10-20 上海伯豪医学检验所有限公司 甄别肺部微小结节良恶性的外周血基因标志物及其用途
AU2017277784B2 (en) 2016-06-08 2022-06-30 Research Development Foundation Systems and methods for automated coronary plaque characterization and risk assessment using intravascular optical coherence tomography
CA3026809A1 (en) * 2016-06-21 2017-12-28 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
EP3580560B1 (en) 2017-02-09 2024-10-02 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
WO2018223066A1 (en) * 2017-06-02 2018-12-06 Veracyte, Inc. Methods and systems for identifying or monitoring lung disease
CN109470855B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌早期诊断用蛋白芯片及试剂盒
EP3728630A4 (en) 2017-12-19 2021-11-17 The Wistar Institute Of Anatomy And Biology COMPOSITIONS AND METHODS OF DIAGNOSING LUNG CANCER USING GENE EXPRESSION PROFILES
KR102028967B1 (ko) 2017-12-28 2019-10-07 한국원자력의학원 Ｒｉｐ1을 포함하는 폐암 전이 진단용 바이오 마커 및 이의 이용
US20210140977A1 (en) 2018-04-16 2021-05-13 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
JP7526102B2 (ja) * 2018-06-22 2024-07-31 ソマロジック・オペレイティング・カンパニー・インコーポレイテッド 改良されたプロテオミクスマルチプレックスアッセイ
WO2020018005A1 (en) * 2018-07-17 2020-01-23 Limited Liability Company "Gero" Devices, methods, compositions and systems for the treatment of aging and age- related disorders
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
AU2019371238B2 (en) * 2018-10-30 2026-02-05 Somalogic Operating Co., Inc. Methods for sample quality assessment
CN109470859A (zh) * 2018-11-04 2019-03-15 华东医院 一种外泌体蛋白作为鉴别肺结节良恶性标志物及其应用
WO2020132520A2 (en) * 2018-12-20 2020-06-25 Veracyte, Inc. Methods and systems for detecting genetic fusions to identify a lung disorder
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
WO2020243574A1 (en) * 2019-05-31 2020-12-03 Delphinus Medical Technologies, Inc. Systems and methods for interactive lesion characterization
US20210027890A1 (en) * 2019-07-24 2021-01-28 ConnSante BioTech, Inc. Detecting, evaluating and predicting system for cancer risk
JP7712913B2 (ja) 2019-09-03 2025-07-24 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
CN115023615A (zh) 2020-01-10 2022-09-06 私募蛋白质体操作有限公司 确定葡萄糖耐量减低的方法
AU2021213150A1 (en) 2020-01-30 2022-08-04 Prognomiq Inc Lung biomarkers and methods of use thereof
JP7766605B2 (ja) 2020-02-10 2025-11-10 ソマロジック オペレーティング カンパニー インコーポレイテッド 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
KR102260915B1 (ko) 2020-02-19 2021-06-04 한국원자력의학원 폐암의 방사선 치료 예후 예측을 위한 생체 표지자
CN111876478B (zh) * 2020-04-28 2025-11-21 中国科学院微生物研究所 肺结节诊断标志物及应用
US20230304099A1 (en) * 2020-08-14 2023-09-28 The Medical College Of Wisconsin, Inc. Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use
JP2023545017A (ja) * 2020-10-02 2023-10-26 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 肺がんの検出及び治療のための方法
CN113960235B (zh) * 2020-10-10 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 生物标志物在制备肺癌检测试剂中的用途和方法
CA3195924A1 (en) 2020-10-20 2022-04-28 Laura Mae SAMPSON Cardiovascular event risk prediction
JP2024516522A (ja) * 2021-03-31 2024-04-16 プログノミック インコーポレイテッド マルチオミクス評価
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
US20220328134A1 (en) 2021-03-31 2022-10-13 PrognomIQ, Inc. Multi-omic assessment
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
EP4711762A1 (en) 2021-09-13 2026-03-18 Prognomiq Inc Enhanced detection and quantitation of biomolecules
MX2024008874A (es) 2022-01-21 2024-07-29 Somalogic Operating Co Inc Metodos de evaluacion de calidad de muestras.
CN118829883A (zh) 2022-04-24 2024-10-22 私募蛋白质体操作有限公司 用于样品质量评估的方法
AU2023259062A1 (en) 2022-04-24 2024-09-12 Somalogic Operating Co., Inc. Methods for sample quality assessment
CN118765373A (zh) 2022-04-24 2024-10-11 私募蛋白质体操作有限公司 用于样品质量评估的方法
EP4515246A1 (en) 2022-04-24 2025-03-05 SomaLogic Operating Co., Inc. Methods for sample quality assessment
WO2023244582A1 (en) * 2022-06-13 2023-12-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Lung cancer-related biomarkers and methods of using the same
WO2024010854A1 (en) * 2022-07-07 2024-01-11 Diagnose Early, Inc. Rapid generation of breath-based health reports and systems for use in the same
AU2023308198A1 (en) 2022-07-14 2024-11-14 Somalogic Operating Co., Inc. Methods of assessing dementia risk
KR20250036127A (ko) 2022-07-14 2025-03-13 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 샘플 품질 평가 방법
EP4591066A2 (en) 2022-09-23 2025-07-30 SomaLogic Operating Co., Inc. Methods of assessing tobacco use status
US20240200125A1 (en) * 2022-12-16 2024-06-20 Droplet Biosciences, Inc. Analysis of effluent
CN116539894A (zh) * 2023-05-08 2023-08-04 复旦大学附属中山医院 Capg在制备病理性心肌肥厚检测试剂中的应用
CN121336096A (zh) 2023-07-06 2026-01-13 私募蛋白质体操作有限公司 干燥生物基质中的靶分子的检测
CN120559238A (zh) * 2025-05-27 2025-08-29 中国人民解放军总医院第一医学中心 蛋白质标志物在制备用于肺磨玻璃结节良恶性鉴别的产品中的应用

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20040254101A1 (en) 1995-06-06 2004-12-16 Human Genome Sciences, Inc. Colon specific gene and protein and cancer
AU6688598A (en) 1997-03-07 1998-09-22 University Of Florida Method for diagnosing and staging prostate cancer
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
EP1215500B1 (en) 1999-09-10 2008-07-09 Takashi Muramatsu Early cancer tumor marker
EP1472352A4 (en) 2000-03-06 2005-10-12 Smithkline Beecham Corp NEW COMPOUNDS
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US6576423B2 (en) 2000-12-08 2003-06-10 The Board Of Regents Of The University Of Nebraska Specific mucin expression as a marker for pancreatic cancer
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20040009489A1 (en) 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
JP4679149B2 (ja) 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 ヒト膵癌に関連する遺伝子およびポリペプチド
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
AU2003294828A1 (en) 2002-12-17 2004-07-09 Sinogenomax Co. Ltd. Chinese National Human Genomecenter Specific markers for pancreatic cancer
WO2004061410A2 (en) 2002-12-18 2004-07-22 Ciphergen Biosystems, Inc. Serum biomarkers in lung cancer
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7767391B2 (en) 2003-02-20 2010-08-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
CA2516591A1 (en) 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004099432A2 (en) 2003-05-02 2004-11-18 The Johns Hopkins University Identification of biomarkers for detecting pancreatic cancer
CN1455257A (zh) * 2003-05-23 2003-11-12 北京师范大学 一种利用表面修饰蛋白芯片进行肺癌诊断方法
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
AU2004264948A1 (en) 2003-08-15 2005-02-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Multifactorial assay for cancer detection
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
US20070148648A1 (en) 2003-11-04 2007-06-28 Martin Dugas Method for distinguishing who classified aml subtypes
EP1723428A2 (en) 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
WO2005086891A2 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
WO2005103281A2 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20070275422A1 (en) 2004-07-26 2007-11-29 The Board Of Trustees Of The Leland Stanford Jr. U Methods and Compositions for Detecting Pancreatic Disease
KR20070043868A (ko) 2004-08-02 2007-04-25 칠드런'즈 메디컬 센터 코포레이션 암에 대한 혈소판 바이오마커
ATE483979T1 (de) 2004-08-10 2010-10-15 Oncotherapy Science Inc Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
JP2006053113A (ja) * 2004-08-16 2006-02-23 Medical Proteoscope Co Ltd 肺腺癌リンパ節転移診断方法及び診断キット
WO2006052731A2 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US8632983B2 (en) 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1904649A2 (en) 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007015947A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
US7582441B1 (en) 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
KR20080073740A (ko) * 2005-11-10 2008-08-11 유니버시티 오브 캔터키 폐암 진단 검사
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP3153860A3 (en) 2005-12-22 2017-06-14 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
NZ593224A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (fap) for colorectal cancer prognosis
AU2007211085A1 (en) 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
CA2641315A1 (en) 2006-02-06 2007-08-16 Tethys Bioscience, Inc. Osteoporosis associated markers and methods of use thereof
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
CA3086149A1 (en) 2006-04-04 2007-10-11 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
WO2007146229A2 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US20080090258A1 (en) 2006-06-28 2008-04-17 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
EP2087140A2 (en) * 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
ES2442919T3 (es) 2007-03-27 2014-02-14 Immunovia Ab Firma/marcadores de proteínas para la detección de adenocarcinoma
RU2376372C2 (ru) 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2153232A1 (en) * 2007-05-18 2010-02-17 Duke University Serum biomarkers for the early detection of lung cancer
WO2008153814A2 (en) 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
MX344253B (es) * 2007-07-17 2016-12-09 Somalogic Inc Metodo para generar aptameros con constantes de disociacion mejoradas.
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
WO2009039023A2 (en) * 2007-09-18 2009-03-26 Board Of Regents Of The University Of Texas System Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
EP2238455A4 (en) 2008-01-18 2011-03-02 Vatrix Medical Inc DIAGNOSTIC BIOMARKERS FOR VASCULAR ANEVISM
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
SI2340506T1 (sl) * 2008-09-09 2016-02-29 Somalogic, Inc. Biomarkerji za pljučni rak in njihove uporabe
US20120143805A1 (en) 2008-09-09 2012-06-07 Somalogic, Inc. Cancer Biomarkers and Uses Thereof
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20120165217A1 (en) 2008-10-06 2012-06-28 Somalogic, Inc. Cancer Biomarkers and Uses Thereof
CA2741117A1 (en) 2008-10-30 2010-05-06 Centre De Recherche Public De La Sante Biomarkers for heart failure
US8541170B2 (en) 2008-11-17 2013-09-24 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
EP2366162A1 (en) 2008-11-18 2011-09-21 Collabrx, Inc. Individualized cancer treatment
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
PT2264183T (pt) 2009-06-09 2017-03-14 Gendiag Exe Sl Marcadores de risco para doença cardiovascular
EA201270020A1 (ru) 2009-06-15 2012-07-30 Кардиодкс, Инк. Определение риска развития атеросклеротической болезни сердца
AU2010284199A1 (en) 2009-08-19 2012-04-05 The Cleveland Clinic Foundation Marker detection for characterizing the risk of cardiovascular disease or complications thereof
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
US9683996B2 (en) 2009-10-22 2017-06-20 The Regents Of The University Of California Assessment of solid tumor burden
US9217747B2 (en) 2009-10-29 2015-12-22 Health Diagnostic Laboratory, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20120245235A1 (en) 2009-12-01 2012-09-27 Compenda Bioscience, Inc Classification of cancers
CA2783536A1 (en) 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
WO2011094483A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
WO2011100472A1 (en) 2010-02-10 2011-08-18 The Regents Of The University Of California Salivary transcriptomic and proteomic biomarkers for breast cancer detection
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20110256545A1 (en) * 2010-04-14 2011-10-20 Nancy Lan Guo mRNA expression-based prognostic gene signature for non-small cell lung cancer
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
CA2809282C (en) 2010-09-27 2017-09-12 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
EP2702411A4 (en) * 2011-04-29 2015-07-22 Cancer Prevention & Cure Ltd METHOD FOR IDENTIFICATION AND DIAGNOSIS OF LUNG DISEASES USING CLASSIFICATION SYSTEMS AND KITS THEREFOR
JP6652781B2 (ja) 2011-09-30 2020-02-26 ソマロジック・インコーポレーテッド 心血管系リスクイベントの予測およびその使用
JP5986638B2 (ja) 2011-10-24 2016-09-06 ソマロジック・インコーポレーテッド 肺癌バイオマーカーおよびその使用
CN104812913B (zh) 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
SG10202006426QA (en) 2013-11-21 2020-08-28 Somalogic Inc Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Also Published As

Publication number Publication date
US20180275143A1 (en) 2018-09-27
JP2013532295A (ja) 2013-08-15
CA2801110C (en) 2021-10-05
BR112012032537A2 (pt) 2017-05-23
CN104777313B (zh) 2017-09-26
SG10201508656VA (en) 2015-11-27
CN102985819B (zh) 2015-04-15
BR112012032537B1 (pt) 2021-03-02
AU2011274422B2 (en) 2016-02-11
JP5905003B2 (ja) 2016-04-20
KR20130129347A (ko) 2013-11-28
IL223295A0 (en) 2013-02-03
BR112012032537B8 (pt) 2022-10-18
US20120101002A1 (en) 2012-04-26
SG186953A1 (en) 2013-02-28
CN104777313A (zh) 2015-07-15
EP2591357A4 (en) 2014-01-01
CA2801110A1 (en) 2012-01-12
WO2012006632A2 (en) 2012-01-12
CN102985819A (zh) 2013-03-20
MX2012014268A (es) 2013-02-12
US20130116150A1 (en) 2013-05-09
EP2591357A2 (en) 2013-05-15
WO2012006632A3 (en) 2012-05-18
AU2011274422A1 (en) 2012-12-20
IL223295A (en) 2016-11-30
KR101870123B1 (ko) 2018-06-25
US11221340B2 (en) 2022-01-11

Similar Documents

Publication Publication Date Title
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
WO2014201516A3 (en) Biomarker identification
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
MX346801B (es) Métodos y composiciones para trastornos relacionados con la proliferación celular.
MX373248B (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
BR112018015698A2 (pt) ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos?
ATE554389T1 (de) Apex als marker für lungenkrebs
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
WO2016091888A3 (en) Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
CY1121790T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
MX374601B (es) Procedimientos y series para su uso en los mismos.